APA (7th ed.) Citation

S, K., Z, S., KA, R., JM, F., L, C., AS, R., . . . KT, F. (2026). Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I. JCO precision oncology, 10(6), e2500769. https://doi.org/10.1200/PO-25-00769

Chicago Style (17th ed.) Citation

S, Kummar, et al. "Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I." JCO Precision Oncology 10, no. 6 (2026): e2500769. https://doi.org/10.1200/PO-25-00769.

MLA (9th ed.) Citation

S, Kummar, et al. "Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I." JCO Precision Oncology, vol. 10, no. 6, 2026, p. e2500769, https://doi.org/10.1200/PO-25-00769.